Cenobamate Designated Promising Innovative Medicine (PIM) by the UK’s MHRA for Treatment of Drug-Resistant Focal-Onset Seizures in Adults

    NEXT STORY
    Burning Rock Reports Second Quarter 2020 Financial Results
    PREV STORY
    Genesis HealthCare Reports Second Quarter 2020 Results
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company’s Board of Directors

    author_avatar
    NASDAQ Market News

    Progressive Care Launches New Discharge(RX) Program to Improve Engagement Between Patients and Hospitals

    MIAMI, July 10, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB:RXMD), a personalized healthcare ...

    author_avatar
    NASDAQ Market News

    US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time

    author_avatar
    NASDAQ Market News